About Gliknik

Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. In addition to its stradomerTM program for autoimmune diseases, Gliknik also has commercial rights to two cancer immunomodulator drugs that are in multiple dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma.